NCT00809510 is a Phase 2 clinical trial of ABT-089 in Alzheimer's Disease, sponsored by Abbott.

Who is sponsoring NCT00809510?

NCT00809510 is sponsored by Abbott.

What drugs are being tested in NCT00809510?

Interventions in NCT00809510: ABT-089.

What condition does NCT00809510 study?

NCT00809510 studies Alzheimer's Disease.

Is NCT00809510 still recruiting?

NCT00809510 is currently terminated. Last updated 1 September 2011.

Last reviewed 2011-09-01 · How we verify

NCT00809510

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Terminated Phase 2 Last updated 1 September 2011

What this trial tests

Phase 2 trial testing ABT-089 in Alzheimer's Disease in 63 participants. Terminated before completion.

Timeline

1 January 2009

Primary endpoint
1 June 2009

Quick facts

Lead sponsor	Abbott
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	63
Start date	1 January 2009
Primary completion	1 June 2009
Sites	22 locations across United States

Drugs / interventions tested

ABT-089 — full drug profile →

Conditions studied

Alzheimer's Disease — all drugs for Alzheimer's Disease →

Sponsor

Abbott — full company profile →

Who can join

Adults 55 to 90, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)
Time frame: Month 1, 2, 4, 6

Sponsor's own description

The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Systematic Review on Drugs Acting as Nicotinic Acetylcholine Receptor Agonists in the Treatment of Dementia.
Crestini A, Carbone E, Rivabene R, Ancidoni A, et al · · 2024 · cited 11× · PMID 38334629 · DOI 10.3390/cells13030237

Verify or expand the search:

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting

Other Abbott trials

Trials by the same sponsor.

NCT06217393 — Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia · Phase 3 · completed
NCT05370703 — A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treat · completed
NCT05519514 — Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects · Phase 1 · completed
NCT04784208 — A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY) · unknown
NCT05175131 — Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00809510 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbott
Last refreshed: 1 September 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00809510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing